Novo Holdings, the controlling shareholder of Novo Nordisk , hopes to double the size of its recently acquired contract ...

The new plant will be one of the largest manufacturing investments in Novo Nordisk’s history and will add 1.4 million sq ft of production space for aseptic manufacturing and finished production ...

Novo Nordisk has started building its first brand-new manufacturing facility in Denmark since the millennium, saying it plans to spend around DKK 8.5 billion ($1.2 billion) on the plant.

Novo Holdings plans to double its newly acquired contract drugmaker, Catalent, within five years, focusing on U.S. manufacturing. The $16.5 billion acquisition is aimed at enhancing supply chains amid ...

Novo Nordisk could find its growth hampered even in the short term if it runs into complications at new production facilities. In addition, the company is facing scrutiny over its pricing ...

It's still investing billions in spinning up new manufacturing facilities to ensure that supply capacity stops being a constraint on growth. What's more, Novo Nordisk is in exactly the same ...

While the recent launches of GLP-1 drugs from Novo Nordisk ... run of production investments, from its $5.3 billion outlay for a Mounjaro and Zepbound active pharmaceutical ingredients plant ...

The firm then sold three of Catalent's plants used to complete the drug manufacturing process to Novo Nordisk for $11 billion as part of ... Trump has said he will hit China with new tariffs on the ...